The knowns and unknowns of teprotumumab for thyroid eye disease. (2021)
Attributed to:
Plasma-cell depletion therapy for severe Graves' disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2213-8587(21)00076-0
PubMed Identifier: 33865499
Publication URI: http://europepmc.org/abstract/MED/33865499
Type: Journal Article/Review
Volume: 9
Parent Publication: The lancet. Diabetes & endocrinology
Issue: 6
ISSN: 2213-8587